Table 1 Patient and tumor characteristics
Characteristic | n = 102 |
|---|---|
Age (years) | |
Median | 59 |
Interquartile range | 11 |
Gender (n, %) | Â |
Male | 79 (77.5) |
Female | 23 (22.5) |
Performance status (n, %) | |
0 | 83 (81.4) |
1 | 19 (18.6) |
Tumor location (n, %) | |
Oral cavity | 8 (7.8) |
Nasopharynx | 6 (5.9) |
Oropharynx | 54 (52.9) |
Hypopharynx | 9 (8.8) |
Larynx | 17 (16.7) |
Occult primary | 7 (6.9) |
Other | 1 (0.8) |
HPV status of oropharyngeal tumors (n, %) | |
Negative | 21 (38.9) |
Positive | 32 (59.3) |
NA | 1 (1.8) |
Tumor differentiation status (n, %) | |
Well-differentiated | 9 (8.8) |
Moderately differentiated | 26 (25.5) |
Poorly differentiated | 35 (34.3) |
Undifferentiated | 3 (2.9) |
Not assessed | 29 (28.4) |
Induction chemotherapy (n, %) | |
Yes | 37 (36.3) |
No | 65 (63.7) |
Concomitant chemotherapy (n, %) | |
Cisplatin or carboplatin | 86 (84.3) |
Cetuximab w/o Gemcitabine | 16 (15.7) |
Tumor stage (n, %) | |
Tx | 6 (5.9) |
T1 or T2 | 56 (54.9) |
T3 or T4 | 40 (39.2) |
Nodal stage (n, %) | |
N2a or N2b | 64 (62.7) |
N2c | 33 (32.4) |
N3 | 5 (4.9) |